Bortezomib in Systemic Light-Chain Amyloidosis

Part of the Milestones in Drug Therapy book series (MDT)


The treatment for immunoglobin light-chain amyloidosis has included high-dose chemotherapy with stem cell transplantation. This effective technique is only applicable to approximately 20% of patients. Standard dose chemotherapy has included melphalan with dexamethasone. This regimen results in response rates in excess of 50%. With the introduction of IMID therapy, the combination of thalidomide or lenalidomide with dexamethasone has produced respectable response rates, but tolerance of patients with amyloidosis to IMID’s is less than in patients with multiple myeloma. The introduction of bortezomib for the management of light-chain amyloidosis is reviewed in this chapter. Bortezomib is highly active both as a single agent and in combination with corticosteroids in the treatment of immunoglobulin light-chain amyloidosis, with high hematologic and organ response rates reported. The agent can be used with renal insufficiency, including dialysis dependence. The agent has not been extensively tested in patients with class 3–4 heart failure.


Stem Cell Transplantation Light Chain Brain Natriuretic Peptide Amyloid Fibril Organ Response 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Merlini G, Westermark P (2004) The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies. J Intern Med 255:159–178PubMedCrossRefGoogle Scholar
  2. 2.
    Salant DJ, Sanchorawala V, D’Agati VD (2007) A case of atypical light chain deposition disease–diagnosis and treatment. Clin J Am Soc Nephrol 2:858–867PubMedCrossRefGoogle Scholar
  3. 3.
    Gertz MA, Merlini G, Treon SP (2004) Amyloidosis and Waldenstrom’s macroglobulinemia. Hematology Am Soc Hematol Educ Program 257–282.Google Scholar
  4. 4.
    Merlini G, Stone MJ (2006) Dangerous small B-cell clones. Blood 108:2520–2530PubMedCrossRefGoogle Scholar
  5. 5.
    Comenzo RL (2007) Managing systemic light-chain amyloidosis. J Natl Compr Canc Netw 5:179–187PubMedGoogle Scholar
  6. 6.
    Blade J, Samson D, Reece D et al (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 102:1115–1123PubMedCrossRefGoogle Scholar
  7. 7.
    Durie BG, Harousseau JL, Miguel JS et al (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467–1473PubMedCrossRefGoogle Scholar
  8. 8.
    Gertz MA, Comenzo R, Falk RH et al (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol 79:319–328PubMedCrossRefGoogle Scholar
  9. 9.
    Gertz MA (2004) The classification and typing of amyloid deposits. Am J Clin Pathol 121:787–789PubMedCrossRefGoogle Scholar
  10. 10.
    Palladini G, Malamani G, Co F et al (2001) Holter monitoring in AL amyloidosis: prognostic implications. Pacing Clin Electrophysiol 24:1228–1233PubMedCrossRefGoogle Scholar
  11. 11.
    Feng D, Edwards WD, Oh JK et al (2007) Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation 116:2420–2426PubMedCrossRefGoogle Scholar
  12. 12.
    Sawyer DB, Skinner M (2006) Cardiac amyloidosis: shifting our impressions to hopeful. Curr Heart Fail Rep 3:64–71PubMedCrossRefGoogle Scholar
  13. 13.
    Kawakami K, Abe H, Harayama N, Nakashima Y (2003) Successful treatment of severe orthostatic hypotension with erythropoietin. Pacing Clin Electrophysiol 26:105–107PubMedCrossRefGoogle Scholar
  14. 14.
    Vita G, Mazzeo A, Di Leo R, Ferlini A (2005) Recurrent syncope as persistently isolated feature of transthyretin amyloidotic polyneuropathy. Neuromuscul Disord 15:259–261PubMedCrossRefGoogle Scholar
  15. 15.
    Klein AL, Tajik AJ (1991) Doppler assessment of pulmonary venous flow in healthy subjects and in patients with heart disease. J Am Soc Echocardiogr 4:379–392PubMedGoogle Scholar
  16. 16.
    Bellavia D, Pellikka PA, Abraham TP et al (2008) Evidence of impaired left ventricular systolic function by Doppler myocardial imaging in patients with systemic amyloidosis and no evidence of cardiac involvement by standard two-dimensional and Doppler echocardiography. Am J Cardiol 101:1039–1045PubMedCrossRefGoogle Scholar
  17. 17.
    Lebovic D, Hoffman J, Levine BM et al (2008) Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. Br J Haematol 143(3):369–373PubMedCrossRefGoogle Scholar
  18. 18.
    Gertz MA (2008) Troponin in hematologic oncology. Leuk Lymphoma 49:194–203PubMedCrossRefGoogle Scholar
  19. 19.
    Dispenzieri A, Gertz MA, Kyle RA et al (2004) Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 22:3751–3757PubMedCrossRefGoogle Scholar
  20. 20.
    Dispenzieri A, Gertz MA, Kyle RA et al (2004) Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 104:1881–1887PubMedCrossRefGoogle Scholar
  21. 21.
    Gertz M, Lacy M, Dispenzieri A, Hayman S, Kumar S, Buadi F, Leung N, Litzow M (2008) Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. Leuk Lymphoma 49:36–41PubMedCrossRefGoogle Scholar
  22. 22.
    Gertz MA, Kyle RA (1989) Primary systemic amyloidosis–a diagnostic primer. Mayo Clin Proc 64:1505–1519PubMedCrossRefGoogle Scholar
  23. 23.
    Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR (2005) Amyloidosis: diagnosis and management. Clin Lymphoma Myeloma 6:208–219PubMedCrossRefGoogle Scholar
  24. 24.
    Kyle RA, Gertz MA (1995) Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 32:45–59PubMedGoogle Scholar
  25. 25.
    Palladini G, Kyle RA, Larson DR, Therneau TM, Merlini G, Gertz MA (2005) Multicentre versus single centre approach to rare diseases: the model of systemic light chain amyloidosis. Amyloid 12:120–126PubMedCrossRefGoogle Scholar
  26. 26.
    Sanchorawala V, Seldin DC, Magnani B, Skinner M, Wright DG (2005) Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplant 36:597–600PubMedCrossRefGoogle Scholar
  27. 27.
    Lachmann HJ, Gallimore R, Gillmore JD et al (2003) Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 122:78–84PubMedCrossRefGoogle Scholar
  28. 28.
    Skinner M, Sanchorawala V, Seldin DC et al (2004) High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 140:85–93PubMedGoogle Scholar
  29. 29.
    Gertz MA, Lacy MQ, Dispenzieri A et al (2007) Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. Haematologica 92:1415–1418PubMedCrossRefGoogle Scholar
  30. 30.
    Goodman HJ, Gillmore JD, Lachmann HJ, Wechalekar AD, Bradwell AR, Hawkins PN (2006) Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. Br J Haematol 134:417–425PubMedCrossRefGoogle Scholar
  31. 31.
    Wiseman RL, Powers ET, Kelly JW (2005) Partitioning conformational intermediates between competing refolding and aggregation pathways: insights into transthyretin amyloid disease. Biochemistry 44:16612–16623PubMedCrossRefGoogle Scholar
  32. 32.
    Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar S (2007) Transplantation for amyloidosis. Curr Opin Oncol 19:136–141PubMedCrossRefGoogle Scholar
  33. 33.
    Palladini G, Perfetti V, Obici L et al (2004) Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 103:2936–2938PubMedCrossRefGoogle Scholar
  34. 34.
    Jaccard A, Moreau P, Leblond V et al (2007) High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 357:1083–1093PubMedCrossRefGoogle Scholar
  35. 35.
    Gertz MA, Kyle RA (1990) Acute leukemia and cytogenetic abnormalities complicating melphalan treatment of primary systemic amyloidosis. Arch Intern Med 150:629–633PubMedCrossRefGoogle Scholar
  36. 36.
    Gertz MA, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Kyle RA (2008) Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis. Haematologica 93(9):1402–1406PubMedCrossRefGoogle Scholar
  37. 37.
    Palumbo A, Bringhen S, Liberati AM et al (2008) Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized, controlled trial. Blood 112(8):3107–3114PubMedCrossRefGoogle Scholar
  38. 38.
    Mateos MV, Hernandez JM, Hernandez MT et al (2006) Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 108:2165–2172PubMedCrossRefGoogle Scholar
  39. 39.
    Kastritis E, Dimopoulos MA (2007) The evolving role of lenalidomide in the treatment of hematologic malignancies. Expert Opin Pharmacother 8:497–509PubMedCrossRefGoogle Scholar
  40. 40.
    Palladini G, Perfetti V, Perlini S et al (2005) The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 105:2949–2951PubMedCrossRefGoogle Scholar
  41. 41.
    Cohen AD, Zhou P, Chou J et al (2007) Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/− thalidomide for systemic light-chain amyloidosis: results of a phase II trial. Br J Haematol 139:224–233PubMedCrossRefGoogle Scholar
  42. 42.
    Wechalekar AD, Gillmore JD, Lachmann HJ, Offer M, Hawkins PN (2006) Efficacy and safety of bortezomib in systemic AL amyloidosis – a preliminary report (abstract). Blood 108:129Google Scholar
  43. 43.
    SV RDE, Hegenbart U, Merlini G, Palladini G, Fermand J, Vescio RA, Liu X, Elsayed YA, Comenzo RL (2007) Phase I/II study of bortezomib (B) in patients with systemic AL-amyloidosis (AL). JCO 25:453sGoogle Scholar
  44. 44.
    Dispenzieri A, Lacy MQ, Zeldenrust SR et al (2007) The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 109:465–470PubMedCrossRefGoogle Scholar
  45. 45.
    Sanchorawala V, Wright DG, Rosenzweig M et al (2007) Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 109:492–496PubMedCrossRefGoogle Scholar
  46. 46.
    Takayama S, Reed JC, Homma S (2003) Heat-shock proteins as regulators of apoptosis. Oncogene 22:9041–9047PubMedCrossRefGoogle Scholar
  47. 47.
    Sitia R, Palladini G, Merlini G (2007) Bortezomib in the treatment of AL amyloidosis: targeted therapy? Haematologica 92:1302–1307PubMedCrossRefGoogle Scholar
  48. 48.
    Zhang N, Ahsan MH, Zhu L, Sambucetti LC, Purchio AF, West DB (2005) Regulation of IkappaBalpha expression involves both NF-kappaB and the MAP kinase signaling pathways. J Inflamm (Lond) 2:10CrossRefGoogle Scholar
  49. 49.
    Anderson KC, Alsina M, Bensinger W et al (2007) Multiple myeloma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 5:118–147PubMedGoogle Scholar
  50. 50.
    Wechalekar AD, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD (2008) Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica 93:295–298PubMedCrossRefGoogle Scholar
  51. 51.
    Fauble VS, Shah-Reddy I (2006) Primary amyloidosis treated with bortezomib with a clinical and radiological response (abstract 5111). Blood 108Google Scholar
  52. 52.
    Kastritis E, Anagnostopoulos A, Roussou M et al (2007) Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica 92:1351–1358PubMedCrossRefGoogle Scholar
  53. 53.
    Roussou M, Kastritis E, Migkou M et al (2008) Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leuk Lymphoma 49:890–895PubMedCrossRefGoogle Scholar
  54. 54.
    Leung N, Dispenzieri A, Fervenza FC et al (2005) Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis. Am J Kidney Dis 46:270–277PubMedCrossRefGoogle Scholar

Copyright information

© Springer Basel AG 2011

Authors and Affiliations

  1. 1.Division of HematologyMayo ClinicRochesterUSA
  2. 2.Hematology ServiceMemorial Sloan Kettering Cancer CenterNew YorkUSA

Personalised recommendations